ArticleBMJ open2022

Safety and tolerability of a multilineage-differentiating stress-enduring cell-based product in neonatal hypoxic-ischaemic encephalopathy with therapeutic hypothermia (SHIELD trial): a clinical trial protocol open-label, non-randomised, dose-escalation trial.

Nao Matsuyama et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.